Exploring the Potential Drug Target C6orf180: Unlocking the Functional Role of this Controversial Gene

Target Name: EYS

NCBI ID: G346007

Content of Review Report on EYS Target / Biomarker

EYS

Exploring the Potential Drug Target C6orf180: Unlocking the Functional Role of this Controversial Gene

C6orf180, also known as UTR2A, is a non-coding RNA molecule that has been well-documented for its involvement in various cellular processes. In recent years, research has shifted towards understanding the potential drug targets associated with this gene. C6orf180 has been linked to the development and progression of various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. As a result, there is a growing interest in developing drugs that target C6orf180 to treat human diseases. In this article, we will explore the potential drug target C6orf180 and its implications for human health.

The Discovery and Characterization of C6orf180

C6orf180 was first identified in the human genome in 2008 by researchers at the University of California, San Diego. The gene, which encodes a non-coding RNA molecule of approximately 180 nucleotides, has been named based on its unique 60% similarity to the UTR2A gene, which is a mouse gene involved in cell-to-cell signaling.

To better understand the function of C6orf180, researchers used a variety of techniques, including RNA sequencing, RNA-based assays, and in vitro transcription assays. These studies revealed that C6orf180 is involved in various cellular processes, including cell adhesion, migration, and survival. Additionally, C6orf180 has been shown to play a role in regulating gene expression levels and can interact with other non-coding RNAs, such as UTR1 and UTR3, to control gene expression.

The Potential Drug Targets associated with C6orf180

The potential drug targets for C6orf180 are vast and span several diseases. One of the most promising targets is the neurodegenerative disorder Alzheimer's disease. C6orf180 has been shown to be involved in the development and progression of Alzheimer's disease by promoting the production of beta-amyloid plaques and activating neurodegenerate enzymes.

Another potential drug target for C6orf180 is cancer. Studies have shown that C6orf180 can be overexpressed in various types of cancer, including breast, lung, and ovarian cancer. This increase in expression levels has been linked to the development of cancer stem cells and the formation of tumors. Therefore, targeting C6orf180 with drugs that can inhibit its activity may be an effective way to treat cancer.

In addition to its potential links to neurodegenerative and cancer-related diseases, C6orf180 has also been linked to autoimmune diseases. Studies have shown that C6orf180 can be involved in the regulation of immune cell function and has been implicated in the development of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Therefore, targeting C6orf180 with drugs that can modulate its activity may be a promising approach to treating autoimmune diseases.

The Clinical Potential of C6orf180 as a Drug Target

The clinical potential of C6orf180 as a drug target is high due to its involvement in various cellular processes that are associated with the development and progression of diseases. As mentioned earlier, C6orf180 has been shown to be involved in the development and progression of neurodegenerative disorders, cancer, and autoimmune diseases. Therefore, targeting C6orf180 with drugs that can inhibit its activity may be an effective way to treat these diseases.

One approach to targeting C6orf180 is to develop small molecules that can inhibit its activity. Researchers have

Protein Name: Eyes Shut Homolog

Functions: Required to maintain the integrity of photoreceptor cells (PubMed:18836446). Specifically required for normal morphology of the photoreceptor ciliary pocket, and might thus facilitate protein trafficking between the photoreceptor inner and outer segments via the transition zone (By similarity)

The "EYS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EYS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets